STILNOX Film-coated tablet Ref.[50865] Active ingredients: Zolpidem

5 Dosage and administration

5.1 Dosage in Adults

Use the lowest effective dose for the patient. The recommended initial dose is 5 mg for women and either 5 or 10 mg for men, taken only once per night immediately before bedtime with at least 7-8 hours remaining before the planned time of awakening. If the 5 mg dose is not effective, the dose can be increased to 10 mg. In some patients, the higher morning blood levels following use of the 10 mg dose increase the risk of next day impairment of driving and other activities that require full alertness [see Warnings and Precautions (8.2)]. The total dose of Stilnox should not exceed 10 mg once daily immediately before bedtime. Stilnox should be taken as a single dose and should not be readministered during the same night.

The recommended initial doses for women and men are different because zolpidem clearance is lower in women.

5.2 Special Populations

Elderly or debilitated patients may be especially sensitive to the effects of zolpidem tartrate. Patients with hepatic insufficiency do not clear the drug as rapidly as normal subjects. The recommended dose of Stilnox in both of these patient populations is 5 mg (half tablet) once daily immediately before bedtime [see Warnings and Precautions (8. 2); Use in Specific Populations (11.4)].

Stilnox should not be used in patient with severe hepatic insufficiency [see Contraindications (7)].

5.3 Use with CNS Depressants

Dosage adjustments may be necessary when Stilnox is combined with other CNS depressant drugs because of the potentially additive effects [see Warnings and Precautions (8.1)].

5.4 Administration

The effect of Stilnox may be slowed by ingestion with or immediately after a meal.

6 Dosage forms and strengths

Stilnox is available in 10 mg strength tablets for oral administration.

It is possible to take half of tablet (5mg) if needed [see Special population (2.2)].

13.1 Signs and Symptoms

In postmarketing experience of overdose with zolpidem tartrate alone, or in combination with CNS-depressant agents, impairment of consciousness ranging from somnolence to coma, cardiovascular and/or respiratory compromise, and fatal outcomes have been reported.

13.2 Recommended Treatment

General symptomatic and supportive measures should be used along with immediate gastric lavage where appropriate. Intravenous fluids should be administered as needed. Zolpidem’s sedative hypnotic effect was shown to be reduced by flumazenil and therefore may be useful; however, flumazenil administration may contribute to the appearance of neurological symptoms (convulsions). As in all cases of drug overdose, respiration, pulse, blood pressure, and other appropriate signs should be monitored and general supportive measures employed. Hypotension and CNS depression should be monitored and treated by appropriate medical intervention. Sedating drugs should be withheld following zolpidem overdosage, even if excitation occurs. The value of dialysis in the treatment of overdosage has not been determined, although hemodialysis studies in patients with renal failure receiving therapeutic doses have demonstrated that zolpidem is not dialyzable.

As with the management of all overdosage, the possibility of multiple drug ingestion should be considered. The physician may wish to consider contacting a poison control center for upto-date information on the management of hypnotic drug product overdosage.

The expiry date of the product is indicated on the packaging materials.

Store below 25°C,